Clinical and Translational Medicine (Jun 2022)
FTO‐mediated m6A modification of SOCS1 mRNA promotes the progression of diabetic kidney disease
- Qiang Sun,
- Houfa Geng,
- Meng Zhao,
- Yang Li,
- Xi Chen,
- Qian Sha,
- Peng Lai,
- Daoquan Tang,
- Dongzhi Yang,
- Jun Liang,
- Mengzhe Guo
Affiliations
- Qiang Sun
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy Xuzhou Medical University Xuzhou Jiangsu China
- Houfa Geng
- Department of Endocrinology Xuzhou Central Hospital, Xuzhou Clinical School of Nanjing Medical University Xuzhou Jiangsu China
- Meng Zhao
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy Xuzhou Medical University Xuzhou Jiangsu China
- Yang Li
- Institute of Thoracic Oncology and Department of Thoracic Surgery West China Hospital, Sichuan University Chengdu Sichuan China
- Xi Chen
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy Xuzhou Medical University Xuzhou Jiangsu China
- Qian Sha
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy Xuzhou Medical University Xuzhou Jiangsu China
- Peng Lai
- Department of Endocrinology Xuzhou Central Hospital, Xuzhou Clinical School of Nanjing Medical University Xuzhou Jiangsu China
- Daoquan Tang
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy Xuzhou Medical University Xuzhou Jiangsu China
- Dongzhi Yang
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy Xuzhou Medical University Xuzhou Jiangsu China
- Jun Liang
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy Xuzhou Medical University Xuzhou Jiangsu China
- Mengzhe Guo
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy Xuzhou Medical University Xuzhou Jiangsu China
- DOI
- https://doi.org/10.1002/ctm2.942
- Journal volume & issue
-
Vol. 12,
no. 6
pp. n/a – n/a
Abstract
No abstracts available.Keywords
